NTII Stock Overview
Neurobiological Technologies, Inc. operates under a plan of liquidation and dissolution approved by stockholders in October 2009.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Neurobiological Technologies, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.000001 |
| 52 Week High | US$0.001 |
| 52 Week Low | US$0.000001 |
| Beta | 0 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | -99.98% |
| 5 Year Change | -99.98% |
| Change since IPO | -100.00% |
Recent News & Updates
No updates
Recent updates
No updates
Shareholder Returns
| NTII | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | 0.4% | 1.0% |
| 1Y | n/a | 0.9% | 21.9% |
Return vs Industry: Insufficient data to determine how NTII performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how NTII performed against the US Market.
Price Volatility
| NTII volatility | |
|---|---|
| NTII Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: NTII has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine NTII's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1987 | n/a | n/a | n/a |
Neurobiological Technologies, Inc. operates under a plan of liquidation and dissolution approved by stockholders in October 2009. Previously, it focused on developing investigational drugs for the treatment of human diseases. The company was founded in 1987 and is based in Emeryville, California.
Neurobiological Technologies, Inc. Fundamentals Summary
| NTII fundamental statistics | |
|---|---|
| Market cap | US$27.00 |
| Earnings (TTM) | US$18.67m |
| Revenue (TTM) | US$25.32m |
0.0x
P/E Ratio0.0x
P/S RatioIs NTII overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NTII income statement (TTM) | |
|---|---|
| Revenue | US$25.32m |
| Cost of Revenue | US$0 |
| Gross Profit | US$25.32m |
| Other Expenses | US$6.65m |
| Earnings | US$18.67m |
Last Reported Earnings
Dec 17, 2009
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did NTII perform over the long term?
See historical performance and comparison